Search

Your search keyword '"Buttigieg, Karen R."' showing total 23 results

Search Constraints

Start Over You searched for: Author "Buttigieg, Karen R." Remove constraint Author: "Buttigieg, Karen R." Database Unpaywall Remove constraint Database: Unpaywall
23 results on '"Buttigieg, Karen R."'

Search Results

2. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction

3. 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

4. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

5. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

6. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

7. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

8. Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

9. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

10. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

11. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

12. Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

13. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

14. Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

15. Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19

16. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

17. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

18. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

19. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

20. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

21. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 By Disrupting The Spike-ACE2 interaction

22. Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

Catalog

Books, media, physical & digital resources